Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR - ABL1 transcripts by imatinib therapy

ConclusionSwitching to dasatinib would be a therapeutic option for CP-CML patients who achieved MMR but not DMR by imatinib, especially for patients who wish to discontinue TKI therapy.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research